Sirius Investors

SLXN Stock: Silexion Therapeutics Ltd. Stock Price, Analysis & Insights

Get live slxn stock price $4.07, comprehensive Silexion Therapeutics Ltd. stock analysis, charts, news, and expert forecast. Real-time slxn stock data and investment insights.

4.07
17.44%Today
SLXNSilexion Therapeutics Ltd. • NASDAQ Global Market • Healthcare
Market Cap
2.28M
Volume
1.11M
52W High
63.45
52W Low
3.10

Company Overview

Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.

Company Information

CEO
Ilan Hadar
Sector
Healthcare
Industry
Biotechnology
Employees
11

Contact Information

Address
The Goldyne Savad Institute of Gene Therapy
Country
IL

Investment Analysis & Insights

Key Investment Highlights

  • Market Position: Healthcare leader with 2.28M market capitalization
  • Trading Volume: 1.11M shares traded today
  • Price Range: 52-week range of $3.10 - $63.45
  • Exchange: Listed on NASDAQ Global Market

Financial Metrics

P/E Ratio:-0.13
EPS:$-30.78
Beta:0.04
Avg Volume:382.23K

Market Analysis for Silexion Therapeutics Ltd.

Silexion Therapeutics Ltd. (SLXN) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 2.28M, the company represents a significant player in its market. The stock is currently trading at $4.07 with a negativedaily change of 17.44%.

The company's 11 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -0.13, beta of 0.04, and 52-week price range from $3.10 to $63.45when evaluating investment opportunities.

Why Invest in Silexion Therapeutics Ltd.?

Strengths
  • • Established market presence in Healthcare
  • • Strong financial metrics and market position
  • • Listed on major exchange (NASDAQ Global Market)
  • • Experienced leadership under Ilan Hadar
Investment Considerations
  • • Monitor sector-specific market trends
  • • Track quarterly earnings performance
  • • Consider market volatility and beta
  • • Evaluate long-term growth potential

Related Healthcare Stocks

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.